The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection

Sujin Kim, Min Ji Kim, Chang Hoon Kim, Ju Wan Kang, Ha Kyung Shin, Dong Young Kim, Tae Bin Won, Doo Hee Han, Chae Seo Rhee, Joo Heon Yoon, Hyun Jik Kim

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Here, we studied the IFN-regulated innate immune response against influenza A virus (IAV) infection in the mouse lung and the therapeutic effect of IFN-l2/3 in acute IAV lung infection. For viral infections, IAV (WS/33, H1N1, PR8 H1N1, H5N1) were inoculated into wild-Type mice by intranasal delivery, and IAV mRNA level and viral titer were measured. To compare the antiviral effect of IFNs in vivo in the lung, neutralizing antibodies and recombinant IFNs were used. After intranasal inoculation of IAV into mice, viral infection peaked at 7 days postinfection, and the IAV titer also reached its peak at this time. We found that IFN-b and IFN-l2/3 were preferentially induced after IAV infection and the IFNl2/ 3-mediated innate immune response was specifically required for the induction of IFN-stimulated genes (ISGs) transcription in the mouse respiratory tract. Neutralization of secreted IFN-l2/3 aggravated acute IAV lung infection in mice with intact IFN-b induction; consistent with this finding, the transcription of ISGs was significantly reduced. Intranasal administration of IFN-l2/3 significantly suppressed various strains of IAV infection, including WS/33 (H1N1), PR (H1N1), and H5N1 in the mouse lung, and was accompanied by greater up-regulation of ISGs. Taken together, our data indicate that the IFN-l2/3-mediated innate immune response is necessary to protect the lungs from IAV infection, and intranasally delivered IFN-l2/3 has the potential to be a useful therapeutic strategy for treating acute IAV lung infection.

Original languageEnglish
Pages (from-to)202-212
Number of pages11
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Issue number2
Publication statusPublished - 2017 Feb

Bibliographical note

Funding Information:
This work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by Ministry of Education grant 2016R1D1A1B01014116 (H.J.K.).

Publisher Copyright:
© 2017 by the American Thoracic Society.

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection'. Together they form a unique fingerprint.

Cite this